|Articles|October 13, 2021
Best Practices for 21 CFR Part 11 and GxP Validation for Electronic Records
Author(s)Egnyte
Drug development has dramatically changed over the past ten years. Specifically when it comes to GxP compliance and validation. Many biopharma companies struggle to adopt new technologies because of the uncertainty of how to comply with FDA regulations. In this white paper, Egnyte will chronicle recent technological trends, specific challenges these trends pose for Quality & CSV teams, and best practices for tackling resulting compliance issues.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
FDA and EMA Align on Ten Principles to Guide Artificial Intelligence Use in Drug Development
2
New Phase II Data Suggest Maternal Nipocalimab Does Not Disrupt Infant Immune Development in Severe HDFN
3
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
4
Global by Design: What 2026 Means for Sites, Sponsors, and Trial Operations
5